Glyco-biomarker discovery platforms at CD BioGlyco are able to process various biological samples, and the optimized technology platforms can achieve ultra-high precision to help customers advance projects more accurately and quickly. We have the confidence to provide our customers with the optimal scientific services.

Background

Protein glycosylation is a common post-translational modification sensitive to changes in the cellular environment. Glycosylation plays an important role in most life processes, such as protein folding, cell-to-cell interactions, receptor binding, etc. Abnormal glycosylation is associated with many diseases, including cancer, Parkinson's disease and cardiovascular disease. Glycans are different from nucleic acids and proteins as genetic templates do not directly encode them. Instead, they are dynamically assembled in hundreds of enzymes through more than a dozen complex biosynthetic pathways. Any influence on enzyme activity or any environmental changes will interfere with the final structure of glycans. Ample evidence has demonstrated the presence of abnormal N-glycosylation patterns on tumor cells, and these findings have inspired the search for glycan-based biomarkers in biological samples such as serum and plasma.

Glycans can represent biomarkers, indicating diseases with high sensitivity and specificity, and show great promise in distinguishing between healthy and diseased individuals. However, due to the need for complex sample preparation, the current methods for analyzing glycans are not suitable for clinical laboratories. Levels of complexity associated with protein glycosylation are hindering its development. To transfer the valuable knowledge provided by protein glycosylation to the clinical application, advanced strategies are needed to cope with challenges such as sample preparation, sample throughput, expensive instrumentation, and difficult data analysis.

Our Strategies

CD BioGlyco is experienced in the discovery, validation, and verification of glycan biomarkers. Our technology platforms combine traditional and new technologies to achieve ultra-sensitive detection capabilities, which can be used for single-factor and multi-factor detection of a variety of biological substrates.

Professional Glyco-Biomarker Detection Services, Unlocking the Secrets of Biology

CD BioGlyco offers a cutting-edge glyco-biomarker detection service, providing comprehensive and highly sensitive analysis of glycans and glycopeptides for the discovery and validation of novel disease biomarkers.

• Glycosylation Modification Analysis
  We offer high-throughput glycan modification analysis services. Our researchers use lectin chips and glycoprotein microarray technology to rapidly detect structural changes in sugar chains in biological samples.
• Screening and Validation of Glycobiological Biomarkers
  We use glycomics methods, combined with technologies such as mass spectrometry (MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), to enrich and analyze the structure of sugars in samples, screening for potential biomarkers. Through glycoprotein affinity chromatography and high-throughput glycoprotein magnetic bead array methods, we efficiently identify differentially expressed glycoproteins, improving the sensitivity and specificity of detection.
• Multi-omics Integration Analysis
  We provide multi-omics-based biomarker discovery services, integrating proteomics, metabolomics, and genomics data to construct systems biology models for a comprehensive understanding of disease mechanisms and identification of key biomarkers.

Workflow

Applications

• Our services can be used to support lead compound optimization, understand drug mechanisms of action, and evaluate the safety and efficacy of new biopharmaceuticals through glycomic biomarker analysis.
• Our services can be used to identify glycomic biomarkers associated with host-pathogen interactions, disease susceptibility, and severity, helping to develop new diagnostics and vaccines.
• Our services can be used to identify and validate novel glycomic biomarkers, such as cancer, cardiovascular disease, and metabolic disorders.

Advantages of Us

• Our approach ensures unparalleled sensitivity and specificity, allowing for the detection and quantification of low-abundance glyco-biomarkers that are often missed by conventional methods.
• Our service also boasts high reproducibility and quantitative accuracy, critical for reliable biomarker discovery and validation, minimizing batch effects and inter-sample variability.
• We accommodate both targeted analysis of known glyco-biomarkers and untargeted profiling for comprehensive glycomic or glycoproteomic characterization, ensuring a flexible and adaptable service for your research endeavors.

Publication Data

Frequently Asked Questions

CD BioGlyco provides first-class glycan biomarker discovery platforms to process various types of biological samples. We do our best to help customers with biomedical transformation and our broad vision will provide customers with high-quality technical support. If you are interested in our services, please contact us for more detailed information.

Associated Services

Quick Links

Resources